Role of Hepcidin as A Predictor for Iron Metabolism Disorders and Inflammation in Stage 4 Chronic Kidney Disease Patient with Anemia
DOI:
https://doi.org/10.48047/gscdwg12Keywords:
Key words: Hepcidin, iron metabolism disorders, CKDAbstract
Background: Anemia is more frequent in cases with chronic kidney disease compared to the general population. Aim: To assess the role of hepcidin as a predictor for iron metabolism disorders in stage 4 CKD cases with anemia and to evaluate the role of hepcidin as a predictor for inflammation in stage four chronic kidney disease cases with anemia. Patients and methods: This case-control cross-sectional observational research has been conducted on 64 cases with CKD stage 4 with anemia divided into four groups: Group (A): involved 16 cases with hemoglobin levels below 6 g/dl; Group (B): included 16 cases with hemoglobin concentrations six to nine gram per deciliters; Group (C): included 16 patients with hemoglobin levels above 9-11 g/dl; and Group (D): included 16 healthy subjects as a control group at the Nephrology Unit of the Internal
Medicine Department in Assiut University Hospitals from April 2020 till July 2022. Results: Utilizing the ROC curve, it has been demonstrated that hepcidin may be utilized to discriminate among anemic groups and the control group at a cutoff level of > 6.6 ng/ml, with 100% specificity, 93.7% sensitivity, 100% PPV, and 94.07% NPV (p-value < 0.001 & AUC = 0.996). Conclusion:
Hepcidin was a good predictor for iron metabolism disorders and inflammation in stage 4 CKD patients with anemia. Hepcidin and CRP levels were the highest among patients with Hgb levels below 6 gm/dl. Hepcidin level correlated positively with the increase of ferritin in all patients.
Downloads
References
Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PloS one. 2014 Jan 2;9(1):e84943. 2. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. The lancet. 2017 Mar 25;389(10075):1238-52.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
